NCT04132037

An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 225 (estimated)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Urinary disorders (UD) are common in Multiple Sclerosis (MS) and can necessitate using Intermittent Self Catheterisation (ISC). It is well experienced by patients, has little impact on daily life and improves quality of life. However, studies are lacking on long-term adherence to this treatment as well as on discontinuation factors. Our main objective is to prospectively assessed factors associated with ISC discontinuation 2 years after having introduced this technique.

Detailed description

Urinary disorders (UD) are common in Multiple Sclerosis (MS). About 65% of patients suffering from moderate to severe troubles. In case of voiding dysfunction, the reference treatment is based on intermittent self catheterisation (ISC). UD in spinal cord injury (SCI) patients have been widely studied. They are very common, and are life-threatening in the absence of appropriate care. Management of neurological UD (as those occurring in MS) are well defined. ISC is the gold standard of bladder emptying method in this pathological context, and has been the subject of numerous studies. In SCI, the ISC discontinuation rate varies from 52 to 80% according to the published studies, the main factors of continuation being the autonomy to perform the technique, and the continence rate. However, the results are variable. In case of MS, the studies are lacking, the results concerning the discontinuation rate and factors associated with discontinuation are poor. Our main objective within the French speaking neurology study group (GENULF), is to prospectively assessed factors associated with ISC discontinuation 2 years after having introduced this technique. This predictive study will be multicenter, observational, analytical, and prospective and will not modify current clinical practice. We will record clinical and urinary data at each visit (inclusion, 6 weeks, 6 months, 12 months, and 24 months). We will note also if the patient practice ISC as prescribed in order to identify discontinuation of the ISC.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
OTHER	data record	At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported

Timeline

• Start date: 2019-06-26
• Primary completion: 2021-12-01
• Completion: 2022-12-01
• First posted: 2019-10-18
• Last updated: 2019-10-18

Locations

1 site across 1 country: France